Protein Immuno-engineering against infection outbreaks by variant viruses

• Overview

  As seen in the recent novel coronavirus epidemic, the ability to rapidly develop vaccines and antivirals is a critical public health issue in a globalized and highly mobile society. In this research unit, biotechnology, bioinformatics, virology, and recombinant genetic engineering is used to develop a technology platform for the rapid development of vaccines and antivirals. In the platform, the physical, biological, and immunological properties of recombinant proteins will be analyzed, and the data and samples will be stored and shared within the research unit. Furthermore, the research objective is to establish basic technologies (vaccine seed molecules, DNA aptamers and compounds for antiviral drugs) to prepare for future viral epidemics.

  

Members

Kaori Tsukakoshi (Institute of Engineering / Assistant Professor)
Hitoshi Takemae (Center for Infectious Disease Epidemiology and Prevention Research / Associate Professor)
Mami Ohba (Center for Infectious Disease Epidemiology and Prevention Research / Associate Professor)
Vavricka Jr. Christopher John (Institute of Engineering / Associate Professor)